Merrill maintains Qiagen at sell

Qiagen NV was maintained by Merrill Lynch analyst Erica Whittaker at a sell on news that the company's reported profit numbers were below Merrill's forecasts and consensus. But, when adjusted for related costs and acquisitions, the numbers were generally in line with consensus. Qiagen's outlook for 2006 includes adjusted diluted earnings per share of $0.52 to $0.55, at the top end of Merrill's $0.53 estimate and consensus' $0.53. Shares of the Venlo, The Netherlands, pharmaceutical company were up 68 cents, or 5.44%, at $13.18 on volume of 1,040,186 shares versus the three-month running average of 266,163 shares. (Nasdaq: QGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.